<![CDATA[Ovarian cancer is known as a silent but deadly disease (silent killer) so it is not uncommon for sufferers to end in death. Radiotherapy for ovarian cancer is indicated as adjuvant therapy for advanced stages in an effort to extend survival rate. This review aims to determine the factors that influence survival rates, local control, and toxicity leves in patients receiving radiotherapy for ovarian cancer. This research is a narrative reviw using the PRISMA method. A literature search was conducted in three databases Pubmed, CENTRAL and Science Direct in the 2013-2023 period. The specified keywords are adapted to the terms Medical Subject Headings (MeSH) and research questions using the PEO formula. Articles were selected based on predetermined inclusion and exclusion criteria. There are 9 selected primary articles and included in the narrative reflection. As many as 3 out of 9 studies stated first-line therapy in the form of total debulking surgery of lesions treated before RT as a factor that significantly influenced survival rates, 2 studies stated CA-125 levels before and after RT had a significant effect on survival rates, 2 studies explained that patients with platinum sensitivity and CCC histological subtypes had better survival rates, and 2 other literatures explained that cancer stage at diagnosis, cancer volume, and post-treatment or not after RT also significantly affected survival rates. Ovarian cancer patients who undergo radiotherapy have better survival rate than patients who do not receive radiotherapy with excellent local control and limited radiation related toxicity that is relatively well tolerated by patients]]>
Copyrights © 2025
